[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478435":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":22,"locations":28,"responsibleParty":45,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Henry Ford Health System","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Budesonide","EXPERIMENTAL",null,[13],"Drug: Budesonide",{"label":15,"type":16,"description":11,"interventionNames":11},"nothing","NO_INTERVENTION",[18],{"type":19,"name":9,"description":20,"armGroupLabels":21,"otherNames":11},"DRUG","budesonide starting day 5 after transplant",[9],[23],{"name":24,"role":25,"phone":26,"phoneExt":11,"email":27},"shatha farhan","CONTACT","3137133910","sfarhan1@hfhs.org",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Detroit","Michigan","48202","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-83.04575,42.33143,{"lat":40,"lon":39},[43],{"name":24,"role":25,"phone":44,"phoneExt":11,"email":27},"313-916-5002",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Shatha Farhan","MD","100478435","phase-3-budesonide-prophylaxis-for-engraftment-syndrome-after-hematopoietic-cell-transplantation-100478435",false,"NCT05509933","Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* • Patients 18-80 years of age with a diagnosis of a hematological malignancy\n\n  * Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies\n\nExclusion Criteria:\n\n* • Patients enrolled in investigational clinical trials\n\n  * Sct for non hematologic malignancies","ALL","18 Years","80 Years",{"count":59,"type":60},110,"ESTIMATED","INTERVENTIONAL",[63],"PHASE3","The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.",[66],"Engraftment Syndrome","2026-04-29",{"date":69,"type":70},"2026-05-01","ACTUAL",{"date":72,"type":70},"2022-11-09",{"date":74,"type":60},"2027-12-30",{"name":5,"class":6},1]